Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)

NICE technology appraisal guidance [TA323] Published date:

Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended as possible treatments for anaemia in people having chemotherapy to treat cancer.

What does this mean for me?

If you have anaemia and are having chemotherapy to treat cancer, and your doctor thinks that an erythropoiesis-stimulating agent is the right treatment, you should be able to have the treatment on the NHS.

Erythropoiesis-stimulating agents should be available on the NHS within 3 months of the guidance being issued.

Get involved